Watson Pharmaceuticals names new senior vice president of global operations
WPI | Quote | Chart | News | PowerRating -- Watson Pharmaceuticals, a specialty pharmaceutical company, has appointed Robert Stewart as its new senior vice president of global operations.
In this position, Mr Stewart will have responsibility for global manufacturing, supply chain, quality and technical operations.
The company also announced that Thomas Russillo, executive vice president and president of the generics division, has been named executive vice president of global generics and will head the company's newly formed global generics commercial function.
In this position, Mr Russillo will have overall responsibility for generic sales and marketing for the US and Canada, as well as for all international markets that will be added to Watson following completion of the acquisition of the Arrow Group. Both Mr Stewart and Mr Russillo report to Paul Bisaro, president and CEO of Watson.
Mr Stewart joins Watson following an eight-year career at Abbott Laboratories, where he most recently served as divisional vice president of global supply chain. From 2005 until 2008, Mr Stewart served as divisional vice president of quality assurance.
Mr Russillo was appointed executive vice president and president of the generics division in 2006. Prior to joining Watson, he served as a consultant to the company in connection with the company's integration planning related to the acquisition of Andrx.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
For full details on Watson Pharmaceuticals (WPI) WPI. Watson Pharmaceuticals (WPI) has Short Term PowerRatings at TradingMarkets. Details on Watson Pharmaceuticals (WPI) Short Term PowerRatings is available at This Link.
- Watson and HRA Pharma sign licensing agreement - 02/03/10
- Watson Pharmaceuticals signs licensing agreement with HRA Pharma for ulipristal acetate (UPA) - 02/02/10
- Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook - 02/02/10
- Watson Pharmaceuticals completes acquisition of Eden Biodesign - 02/01/10
- Watson and HRA Pharma Announce Exclusive Licensing Agreement to Commercialize Novel Emergency Contraceptive in the U.S. - 02/01/10
- More News >>


